# RXRX catalysts: RECURSION PHARMACEUTICALS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rxrx/catalysts

> RECURSION PHARMACEUTICALS, INC. (RXRX) has 1 upcoming catalyst. The next is the REC-4881 trial start, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for RXRX?

RECURSION PHARMACEUTICALS, INC. (RXRX) has 1 upcoming catalyst. The next is the REC-4881 trial start, 2H 2027. Press release filed with the SEC (EX-99): "the design, timing of initiation, and outcomes of a registrational trial of REC-4881, including anticipated initiation in the second half of 2027, and the timing of additional details regarding such trial" [Calendar and source filings](https://sec-api.dev/companies/rxrx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001601830-26-000144, https://www.sec.gov/Archives/edgar/data/1601830/000160183026000144/exhibit993-cgapr.htm (retrieved 2026-11-12). Last confirmed 2026-11-02. Cite: https://sec-api.dev/companies/rxrx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | RECURSION PHARMACEUTICALS, INC. |
| Ticker | RXRX (Nasdaq) |
| SEC CIK | 1601830 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/rxrx |

## Cash runway

Cash $549.9M as of 2026-09-30; quarterly burn $77.4M; about 21.3 months of runway at that rate (XBRL company facts, accession 0001601830-26-000145).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [Superoxide topline data readout](https://sec-api.dev/pdufa/superoxide) | RXRX |  | completed, met | "Topline 12-month data from Part 1, shared in September 2024 and at the ISC annual meeting in February 2025, showed that REC-994 met its primary endpoints of safety and tolerability, in-line with Phase 1 results and with no new safety signals observed." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000035/rxrx-20241231.htm)) |
| Sep 2024 | [REC-1245 trial start](https://sec-api.dev/pdufa/rec-1245) | RXRX |  | completed | "Following IND clearance in September 2024, we initiated a Phase 1/2 (DAHLIA) study in December 2024 to evaluate the safety, tolerability, PK/PD, and preliminary efficacy of REC-1245 in unresectable, locally advanced, or metastatic cancers." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000035/rxrx-20241231.htm)) |
| Oct 2024 | [Vancomycin Hydrochloride (vancomycin) trial start](https://sec-api.dev/pdufa/vancomycin) | RXRX | high-risk of CDI | completed | "In October 2024, we initiated a Phase 2 open-label, randomized, 3-arm study (ALDER) to evaluate the rate of recurrence in patients with a high-risk of CDI, who have achieved symptom resolution following treatment with oral vancomycin for 14 days." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000035/rxrx-20241231.htm)) |
| Dec 2024 | [REC-3565 trial start](https://sec-api.dev/pdufa/rec-3565) | RXRX |  | completed | "Following clearance of a CTA by the MHRA in December 2024, we initiated EXCELERIZE, a Phase 1 open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK, PD, and preliminary anti-tumor activity of REC-3565 in 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000039/rxrx-20251231.htm)) |
| Dec 2024 | [REC-1245 trial start](https://sec-api.dev/pdufa/rec-1245) | RXRX | unresectable locally advanced or metastatic cancer | completed | "In December 2024, we initiated a Phase 1/2 open-label, multicenter study to characterize the safety, tolerability, PK, PD, and preliminary anti-tumor activity of REC-1245 in participants with unresectable locally advanced or metastatic cancer." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000039/rxrx-20251231.htm)) |
| February 28, 2025 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000034/exhibit991-10xk24.htm)) |
| Apr 2025 | [REC-3565 trial start](https://sec-api.dev/pdufa/rec-3565) | RXRX |  | completed | "The first patient was dosed in April 2025, and we expect to share early safety and PK monotherapy data in the first half of 2027." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000039/rxrx-20251231.htm)) |
| May 5, 2025 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000074/exhibit991-q0125.htm)) |
| May 6, 2025 | [REC-3964 primary completion](https://sec-api.dev/pdufa/rec-3964) | RXRX | Recurrent Clostridioides Difficile Infection | withdrawn | "NCT06536465 (The Clostridioides Difficile Trial of REC-3964): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-06 (ACTUAL); Lead Sponsor Recursion Pharmaceuticals Inc.; Results First Posted 2025-11-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06536465)) |
| June 30, 2025 | [REC-994 primary completion](https://sec-api.dev/pdufa/rec-994) | RXRX | Cerebral Cavernous Malformation | completed | "NCT05085561 (The Symptomatic Cerebral Cavernous Malformation Trial of REC-994): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Recursion Pharmaceuticals Inc.; Results First Posted 2026-10-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05085561)) |
| August 5, 2025 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000126/exhibit991-q0225.htm)) |
| August 18, 2025 | [REC-2282 primary completion](https://sec-api.dev/pdufa/rec-2282) | RXRX | Neurofibromatosis Type 2 | withdrawn | "NCT05130866 (Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2025-08-18 (ACTUAL); Lead Sponsor Recursion Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05130866)) |
| November 4, 2025 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000164/exhibit991-q0325.htm)) |
| 1H 2026 | [REC-4881 trial start](https://sec-api.dev/pdufa/rec-4881) | RXRX |  | scheduled | "REC-4881 (MEK1/2): First clinical validation of Recursion's platform - disease with no approved pharmacotherapies Biological insight: MEK1/2 inhibition identified as a unique mechanism for FAP Clinical proof: Rapid and durable polyp burden reduction with adverse events consistent with MEK inhibitors What's next: Initiate FDA engagement in 1H26 to align on registrational study design Enrollment of 18+ cohort underway, dose optimization efforts advancing Additional clinical data expected in 1H27 22 Insight Proof points New medicines" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000038/ye25earningsdeck_final.htm)) |
| 1H 2026 | [EXS74539 trial start](https://sec-api.dev/pdufa/rec-4539) | RXRX | SCLC or other select solid tumors | scheduled | "Following completion of this review, we now expect to initiate a Phase 1 trial in the first half of 2026, with the dose escalation study evaluating REC-4539 in patients with SCLC or other select solid tumors." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000039/rxrx-20251231.htm)) |
| February 25, 2026 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000038/exhibit991-10xk25.htm)) |
| May 6, 2026 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports First Quarter Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000077/exhibit991-q0126.htm)) |
| 2H 2026 | [REV102 trial start](https://sec-api.dev/pdufa/rev102) | RXRX |  | scheduled | "REV102 is currently in IND-enabling studies, with the initiation of Phase 1 clinical trials expected in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000119312525156440/d83626dex991.htm)) |
| 2H 2026 | [REC-7735 trial start](https://sec-api.dev/pdufa/rec-7735) | RXRX |  | scheduled | "Go/no-go decisions on the initiation of Phase 1 studies for REC-7735 (PI3Kα H1047Ri) and REC-102 (ENPP1i) are expected in the second half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000039/rxrx-20251231.htm)) |
| August 5, 2026 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/exhibit991-q0226.htm)) |
| October 22, 2026 | [REC-994 topline data readout](https://sec-api.dev/pdufa/rec-994) | RXRX | Cerebral Cavernous Malformation | completed | "NCT05085561 (The Symptomatic Cerebral Cavernous Malformation Trial of REC-994): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Recursion Pharmaceuticals Inc.; Results First Posted 2026-10-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05085561?tab=results)) |
| October 31, 2026 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000144/exhibit991-q0326.htm)) |
| 2H 2027 | [REC-4881 trial start](https://sec-api.dev/pdufa/rec-4881) | RXRX |  | scheduled | "the design, timing of initiation, and outcomes of a registrational trial of REC-4881, including anticipated initiation in the second half of 2027, and the timing of additional details regarding such trial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000144/exhibit993-cgapr.htm)) |

## Drugs

- [REC-1245](https://sec-api.dev/pdufa/rec-1245): unresectable locally advanced or metastatic cancer
- [REC-2282](https://sec-api.dev/pdufa/rec-2282): Neurofibromatosis Type 2
- [REC-3565](https://sec-api.dev/pdufa/rec-3565): 
- [REC-3964](https://sec-api.dev/pdufa/rec-3964): Recurrent Clostridioides Difficile Infection
- [EXS74539](https://sec-api.dev/pdufa/rec-4539): sclc or other select solid tumors
- [REC-4881](https://sec-api.dev/pdufa/rec-4881): 
- [REC-7735](https://sec-api.dev/pdufa/rec-7735): 
- [REC-994](https://sec-api.dev/pdufa/rec-994): Cerebral Cavernous Malformation
- [REV102](https://sec-api.dev/pdufa/rev102): 
- [Superoxide](https://sec-api.dev/pdufa/superoxide): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rxrx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RXRX catalysts: RECURSION PHARMACEUTICALS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rxrx/catalysts

```bibtex
@misc{secapidev_companies_rxrx_catalysts_20261116,
  title        = {RXRX catalysts: RECURSION PHARMACEUTICALS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rxrx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rxrx_catalysts_20261116","title":"RXRX catalysts: RECURSION PHARMACEUTICALS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rxrx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
